Hiroki Torikai

Medicine & Life Sciences

1. Minor Histocompatibility Antigens 100%
2. Chimeric Antigen Receptors 74%
3. T-Lymphocytes 59%
4. T-Cell Antigen Receptor Specificity 54%
5. HLA Antigens 45%
6. Epitopes 34%
7. CD19-specific chimeric antigen receptor 31%
8. Beauty 30%
9. Clone Cells 28%
10. Cytotoxic T-Lymphocytes 26%
11. HapMap Project 26%
12. H antigen 26%
13. HLA-A24 Antigen 20%
14. Neoplasms 20%
15. T-Lymphocyte Epitopes 20%
16. Hematopoietic Stem Cell Transplantation 19%
17. Leukemia 18%
18. Imatinib Mesylate 18%
19. Immunotherapy 17%
20. HLA-A*33 antigen 17%
21. Single Nucleotide Polymorphism 16%
22. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16%
23. Cathepsin H 15%
24. HLA-A Antigens 15%
25. Tissue Donors 14%
26. Neoplasm Antigens 14%
27. T-Cell Antigen Receptor 14%
28. Pyomyositis 14%
29. HLA-A*02:01 antigen 13%
30. Trisomy Chromosome 8 13%
31. Histiocytic Sarcoma 13%
32. Pancytopenia 13%
33. Leukemia, Myeloid, Chronic Phase 12%
34. HLA-A2 Antigen 12%
35. Hematopoietic Stem Cells 12%
36. Cell Engineering 12%
37. Forensic Anthropology 11%
38. CD4 Antigens 11%
39. Histocompatibility 11%
40. Antigens 11%
41. Bortezomib 11%
42. B-Lymphocytes 11%
43. Cell Line 11%
44. Natural Killer T-Cells 10%
45. Transplants 10%
46. Allogeneic Cells 10%
47. Human papillomavirus 16 10%
48. Genes 10%
49. Homologous Transplantation 10%
50. Alternative Splicing 9%